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Previewscomplex origin may visually appear
similar but have very different underlying
mutational profiles. Integrating histology
with genetic alterations for tumor classi-
fication may be essential to classifying
heterogeneous tumors such as oligoas-
trocytomas, which demonstrate mixed
histologic features and no defining ge-
netic signature. Barriers still exist before
this can become routine clinical practice,
including the cost and complexity of
genetic analysis and the lack of pro-
spective trials validating these genetic
signatures for clinical prognosis. Ulti-
mately, advances in sequencing tech-
nology will enable these biomarkers
to be incorporated into inexpensive and
routine tests.REFERENCES
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Immune checkpoint-blocking therapies have yielded positive clinical data in a series of humanmalignancies.
Recent work from Le and colleagues strongly supports the use of these therapies for mismatch repair-defi-
cient tumors, independent of underlying tumor type. These data suggest the importance of sensing the
consequences of DNA damage in cancer immunotherapy.Over the past few years, therapies that
interfere with T cell checkpoints and, in
particular, the PD-1/PD-L1 axis, have
reached center stage in oncology. Clinical
trials with anti-PD-1 and anti-PD-L1
antibodies have now shown objective
responses in a series of human malig-
nancies, including non-small cell lung
cancer (NSCLC), bladder cancer, renal
cell carcinoma, and Hodgkin’s lymphoma
(Topalian et al., 2012). In non-melanoma
tumors, clinical development of anti-
PD-1 therapy is most advanced for
NSCLC, with recent approval by FDA as
second-line therapy.
A proposed explanation for the activity
of T cell checkpoint blockade in tumors
such as melanoma and NSCLC hasbeen the boosting of T cell reactivity
against ‘‘neo-antigens’’, T cell epitopes
that are newly formed as a consequence
of tumor-specific mutations (Schumacher
and Schreiber, 2015). In line with this,
T cell checkpoint blockade has been
shown to enhance neo-antigen-specific
T cell responses in both diseases (Rizvi
et al., 2015; van Rooij et al., 2013).
Contrary to the data in a number of
other tumor types, clinical testing of
anti-PD-1 has thus far not shown encour-
aging results in colorectal cancer (CRC).
In two trials, a total of 33 CRC patients
were treated with anti-PD-1 therapy and
only 1 patient (3%) experienced an
objective response, which was, however,
a complete response (Topalian et al.,2012). Interestingly, the tumor of this pa-
tient displayed a hyper-mutated pheno-
type, a characteristic of approximately
4% of metastasized colorectal cancers.
Basedon thesedata, Le andcolleagues
hypothesized that patients with mismatch
repair-defects might be particularly
responsive to checkpoint targeting. They
now provide compelling data in favor of
this hypothesis in a recent publication in
the New England Journal of Medicine
(Le et al., 2015). In a phase II study that
evaluated the activity of PD-1 blockade
in 41 patients, 3 cohorts of patients were
included: 11 patients with mismatch
repair-deficient CRC, 21 patients with
mismatch repair-proficient CRC, and 9
patients with mismatch repair-deficientell 28, July 13, 2015 ª2015 Elsevier Inc. 11
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Figure 1. Potential Mechanisms of Action of Anti-PD-1 Therapy in Mismatched Repair-Deficient Tumors
(A) MMR deficiency results in a more diverse neo-antigen repertoire, increasing the chances of a tumor-specific T cell response.
(B) MMR deficiency is associated with the activation of signaling pathways, which leads to a more inflammatory tumor micro-environment.
(C) MMR deficiency leads to cellular stress, which, for instance, promotes T or NK cell accumulation or tumor recognition.
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Previewscancers other than CRC. DNA mismatch-
repair deficiency results in large numbers
of mutations, particularly in regions of re-
petitive DNA sequences, a phenomenon
known as microsatellite instability (MSI).
Mismatch-repair deficiency can arise
as a consequence of inheritance of an
inactive allele of one of the mismatch
repair genes, with subsequent loss of the
remainingwild-type copy, a genetic disor-
der known as Lynch syndrome. Alterna-
tively, sporadic inactivation of mismatch-
repair genes may occur, and, in this trial,
patients with both types of mismatch-
repair deficiency were included. Strik-
ingly, 40% (4 out of 10) of mismatch
repair-deficient CRC patients and 71%
(5 of 7 patients) of mismatch repair-
deficient non-CRC patients experienced
an objective clinical response, whereas
none of the patients with mismatch
repair-proficient tumors responded (0 of
18). Furthermore, CRC patients with
mismatch-repair deficiency had a signifi-
cantly longer progression free survival
(p < 0.001) as well as overall survival
(p = 0.03). An unexpected observation in
this study is that patients with Lynch
syndrome appear to do less well as
compared to mismatch repair-deficient
tumors not linked to Lynch syndrome (3
out of 11 versus 6 out of 6 responders).
Before speculating about possible biolog-
ical explanations, it will be important to
further address this issue in future studies.
Consistent with a large body of litera-
ture on genomic alterations in mismatch
repair-deficient and -proficient tumors,12 Cancer Cell 28, July 13, 2015 ª2015 Elsevthe authors demonstrated a profound
difference in mutational load between
the two. On average, 1,782 somatic
mutations were identified in mismatch
repair-deficient tumors (n = 9) (by far
surpassing the mutational load in
melanoma and NSCLC), whereas, on
average, only 73 somatic mutations
were observed in mismatch repair-profi-
cient tumor (n = 6). A prior analysis
of patients treated with anti-PD-1 has
shown that patients with NSCLC with a
high mutational load have a significantly
higher likelihood of clinical benefit than
patients with less mutated tumors (Rizvi
et al., 2015). A similar, albeit weaker,
correlation was seen for melanoma pa-
tients treated with anti-CTLA-4 therapy
(Snyder et al., 2014). Thus, the data
from Le and coworkers add to the
increasing body of evidence that, in at
least some malignancies, high muta-
tional load can increase the likelihood
of clinical response to immune check-
point-blocking therapies.
The most straightforward explanation
for the heightened activity of anti-PD-1
therapy in mismatch repair-deficient tu-
mors is the increased probability of a
strong neo-antigen-driven T cell response
(model A in Figure 1). Nevertheless, as
also pointed out by the authors, other
potential mechanisms should not be
excluded. First, DNA repair-deficient tu-
mors could potentially be characterized
by changes in signaling transduction
pathways that lead to a more inflamed
tumor micro-environment, for instance,ier Inc.through altered cytokine or chemokine
expression (model B). Alternatively, the
high level of DNA damage in mismatch
repair-deficient tumors may potentially
cause cellular stress that could, for
instance, be sensed by innate immune
cells (model C). Nevertheless, Occam’s
razor would tell us that, in the absence
of additional evidence for such models,
mismatch repair-deficient tumors may
simply look more ‘‘foreign’’ because of
the high number of neo-antigens they
carry.
A remarkable aspect of mismatch
repair-deficient CRC is the frequent loss
of MHC class I expression (in up to
60% of MSI CRC tumors; Dierssen
et al., 2007). How can this be reconciled
with the current clinical data? First, clin-
ical activity may primarily be seen in the
subset of MHC class I proficient tumors,
in which case straightforward MHC
class I immunohistochemistry could be
used as a potential biomarker. Alterna-
tively, it is worth considering that PD-1
therapy may also work in the absence
of tumor-expressed MHC class I. First,
antigen-presenting cells within the tumor
microenvironment may cross-present
MHC class I-restricted tumor antigens
to tumor infiltrating CD8+ T cells in situ,
facilitating an immune response that
can target the tumor microenvironment.
Data from mouse models support the
potential role of such a mechanism in
tumor regression. In addition or alter-
natively, anti-PD-1 therapy may work
through tumor-specific CD4+ T cells.
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PreviewsIndirect support for the latter model
is provided by the observation that
CD4+ TIL in MSI tumors express higher
levels of PD-1 than CD4+ T cells in
MSS (microsatellite stable) tumors (Llosa
et al., 2014) and by the observation that
CD4+ TIL in melanoma—a tumor type
with a lower mutational load—frequently
recognize mutated antigens (Linnemann
et al., 2015). Furthermore, work from
Kreiter et al. (2015) has shown that
MHC class II-restricted T cell responses
can play an important role in tumor con-
trol in a pre-clinical colorectal cancer
model.
The data from Le and colleagues
strongly suggest that immune check-
point blockade can form an attractive
therapy for mismatch repair-deficient
tumors independent of the underlying
tumor type. The fraction of mismatch
repair-deficient tumors for metastasized
cancers is unfortunately not very high:
for instance, roughly 4% of CRC, up
to 11% of ovarian carcinomas, and
18% of endometrial cancers. In future
studies, it will be important to under-
stand if it is feasible to extend cancer
immunotherapy to colorectal tumors
with less profound DNA damage, forinstance through combination check-
point blockade. From a more mecha-
nistic point of view, it will be of interest
to understand whether clinical efficacy
within the mismatch repair-deficient
patient group is primarily restricted
to MHC class I expressing tumors, or
whether anti-PD-1 therapy can also
work in the absence of tumor-expressed
MHC class I.ACKNOWLEDGMENTS
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